Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGT-53 + temozolomide
- Development stage
- Discontinued
- Lead developer
- SynerGene Therapeutics
- Modality
- Gene Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
SGT-53 + temozolomide is a combination therapy consisting of SGT-53, a tumor-targeting nanomedicine carrying the p53 gene, and temozolomide, an alkylating agent. SGT-53 works by restoring p53 function in tumor cells, which can boost anti-tumor immunity and enhance treatment effectiveness. Temozolomide is a prodrug that undergoes spontaneous conversion at physiological pH to form its active metabolite, which then alkylates DNA, causing damage that leads to cancer cell death. This combination was investigated for the treatment of recurrent glioblastoma.
02
Targets
DNATFRC (Transferrin Receptor)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on SGT-53 + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGT-53 + temozolomide.